Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...
Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...
Recursion Pharmaceuticals laid off under 20% of staff following merger with Exscientia. Oxford Nanopore partners with UK Biobank for epigenetic dataset project. Portage Biotech continues strategic ...